<DOC>
	<DOC>NCT00611572</DOC>
	<brief_summary>This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.</brief_summary>
	<brief_title>GABA-glutamate Interactions and Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Inclusion criteria: Ages of 2145 years from all ethnic backgrounds. Male or female. Written informed consent. Exclusion criteria: DSMIV diagnosis for a psychotic, depressive or anxiety disorder. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic abnormality, seizure disorder. Unstable medical condition based on EKG, vital signs, physical examination and laboratory workup (CBC with differential, SMA7, LFTs, TFTs, UA, Utox). History of abnormal EEG. History of severe allergies or multiple adverse drug reactions. Any medication that could interfere with either the safety of the study and/or the outcome measures. Any other conditions which in the opinion of the investigator would preclude participation in the study. History of major psychiatric disorder in first degree relatives. Current substance abuse/dependency determined by urine toxicology. Treatment with medications with CNS effects. Treatment with benzodiazepines within one week prior to testing. Current treatment with medications with psychotropic effects. Education &lt; 10th grade. IQ &lt; 70, MR. NonEnglish speaking.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GABA</keyword>
	<keyword>glutamate</keyword>
	<keyword>NMDA</keyword>
	<keyword>P300</keyword>
	<keyword>MMN</keyword>
</DOC>